I am definitely not going to say that I know enough about clinical trials and what phase 1 or late-stage studies means, but when I see a report, I’m going to report it. This news is a couple of weeks old. Hey, I didn’t say it was breaking news, I just said it was news.
So this article is in regards to Eli Lilly’s Ultra Rapid Lispro insulin which is basically like Humalog, but faster. If I’m not mistaken, it is Eli Lilly’s version of Fiasp, but like I said, I could be wrong.
The good news is that the late-stage studies showed that this insulin “significantly improved post meal blood sugar levels”. That’s the kind of stuff that I like to hear.
I like hearing about new, better insulins.
Obviously, most of that doesn’t matter because majority of us are not going to be able to afford the new insulins, but that’s an ongoing issue (which I’ve been attacked on before from people who don’t know me, so I’m not talking about that in this post.)
I’ve tried Fiasp in the past and I absolutely loved it. Unfortunately, my insurance didn’t cover it, so I couldn’t keep using it. My insurances over the years have switched quite often which means that I’ve switched between Humalog and Novolog.
I haven’t really seen too much of a difference between these two, so I’m hoping that a competitor to Fiasp comes to market and then at least one of the two will be covered by my insurance.
I am very excited about this being approved. I think small molecule medicines will be the next great innovation. Imagine small molecule pills that absorb quicker and act faster, just like skin absorption is a big thing for insulin, the gut works better with small molecules.